Regorafenib: from clinical research to clinical practice
Regorafenib is a new multiple tyrosine kinase inhibitor with anti-cancer and anti-angiogenic activity which application has been recently approved by the Russian Federation in patients with colon cancer and gastrointestinal tumors. The approval of application of regorafenib for the treatment of pati...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Habib O.N.
2017-09-01
|
| Series: | Современная онкология |
| Subjects: | |
| Online Access: | https://modernonco.orscience.ru/1815-1434/article/viewFile/27137/pdf |